FIELD: biomedicine.
SUBSTANCE: group of inventions relates to the treatment of renal cancer. Pharmaceutical combination for treating kidney cancer contains an anti-PD-L1 antibody, which contains a heavy chain CDR1 region having an amino acid sequence presented in SEQ ID NO: 1; heavy chain CDR2 region, having an amino acid sequence presented in SEQ ID NO: 2; heavy chain CDR3 region having an amino acid sequence presented in SEQ ID NO: 3; light chain CDR1 region having an amino acid sequence presented in SEQ ID NO: 7; light chain CDR2 region, having an amino acid sequence presented in SEQ ID NO: 8; and a light chain CDR3 region having an amino acid sequence presented in SEQ ID NO: 9, and anlotinib or a pharmaceutically acceptable salt thereof. Also disclosed are the use of the anti-PD-L1 antibody and anlotinib or a pharmaceutically acceptable salt thereof for preparing a drug for treating kidney cancer and a method of treating kidney cancer.
EFFECT: group of inventions provides a fast response in the treatment of renal cancer and stabilization of the disease.
26 cl, 2 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINED PHARMACEUTICAL COMPOSITION FOR TREATING TUMOUR | 2020 |
|
RU2829637C2 |
| PD-L1 SPECIFIC ANTIBODIES | 2017 |
|
RU2756236C2 |
| ANTI-PD-L1 AND IL-2 CYTOKINES | 2017 |
|
RU2769282C2 |
| BINDING MOLECULES, BINDING PD-L1 AND LAG-3 | 2017 |
|
RU2784388C2 |
| PHARMACEUTICAL COMPOSITION OF THE FUSION PROTEIN OF THE TRANSFORMING GROWTH FACTOR BETA RECEPTOR AND ITS APPLICATION | 2019 |
|
RU2791683C2 |
| NEUTRALIZATION OF LYMPHOCYTE INHIBITORY PATHWAYS | 2015 |
|
RU2734771C2 |
| A NEW COMBINATION FOR USE IN THE TREATMENT OF MALIGNANT NEOPLASMS | 2016 |
|
RU2742494C2 |
| ANTIBODIES AGAINST PD-L1 AND THEIR OPTIONS | 2017 |
|
RU2770590C2 |
| PHARMACEUTICAL COMPOSITION BASED ON ANTIBODY TO PD-L1 AND ITS APPLICATION | 2018 |
|
RU2766590C2 |
| TREATING CANCER WITH COMBINATION OF PD-1 ANTAGONIST AND DINACICLIB | 2014 |
|
RU2705795C2 |
